NASDAQ:BYSI Beyondspring Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Beyondspring Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.23 +0.14 (+0.93 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$15.06Now: $15.23▼$15.5950-Day Range$9.99MA: $12.20▼$15.0952-Week Range$9.38Now: $15.23▼$21.50Volume193,151 shsAverage Volume101,025 shsMarket Capitalization$458.54 millionP/E RatioN/ADividend YieldN/ABeta1.02 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingBeyondspring has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.00, Beyondspring has a forecasted upside of 129.8% from its current price of $15.23.Amount of Analyst CoverageBeyondspring has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesBeyondspring has received 167 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBeyondspring has received 154 “underperform” votes. (Add your “underperform” vote.)Community SentimentBeyondspring has received 52.02% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Beyondspring and other stocks. Vote “Outperform” if you believe BYSI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BYSI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBeyondspring does not currently pay a dividend.Dividend GrowthBeyondspring does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Beyondspring insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 8.27% of the stock of Beyondspring is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Beyondspring are expected to decrease in the coming year, from ($2.08) to ($2.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beyondspring is -7.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beyondspring is -7.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeyondspring has a P/B Ratio of 13.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.22 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BYSI Previous Symbol CUSIPN/A CIK1677940 Webwww.beyondspringpharma.com Phone1-646-305-6387Debt Debt-to-Equity Ratio0.12 Current Ratio3.80 Quick Ratio3.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.12 per share Price / Book13.60Profitability EPS (Most Recent Fiscal Year)($1.55) Net Income$-38,080,000.00 Net MarginsN/A Return on Equity-202.97% Return on Assets-131.58%Miscellaneous EmployeesN/A Outstanding Shares30,108,000Market Cap$458.54 million Next Earnings Date12/16/2020 (Estimated) OptionableNot Optionable $15.23 +0.14 (+0.93 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BYSI News and Ratings via Email Sign-up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter. Beyondspring (NASDAQ:BYSI) Frequently Asked Questions How has Beyondspring's stock price been impacted by COVID-19 (Coronavirus)? Beyondspring's stock was trading at $11.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BYSI shares have increased by 34.2% and is now trading at $15.23. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Beyondspring? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beyondspring in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Beyondspring. When is Beyondspring's next earnings date? Beyondspring is scheduled to release its next quarterly earnings announcement on Wednesday, December 16th 2020. View our earnings forecast for Beyondspring. How were Beyondspring's earnings last quarter? Beyondspring Inc (NASDAQ:BYSI) issued its quarterly earnings data on Thursday, September, 3rd. The company reported ($0.46) EPS for the quarter, topping the Zacks' consensus estimate of ($0.57) by $0.11. View Beyondspring's earnings history. What price target have analysts set for BYSI? 4 brokers have issued 1 year target prices for Beyondspring's shares. Their forecasts range from $25.00 to $46.00. On average, they expect Beyondspring's share price to reach $35.00 in the next year. This suggests a possible upside of 129.8% from the stock's current price. View analysts' price targets for Beyondspring. Who are some of Beyondspring's key competitors? Some companies that are related to Beyondspring include Prestige Consumer Healthcare (PBH), CryoPort (CYRX), MacroGenics (MGNX), Kura Oncology (KURA), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), Ironwood Pharmaceuticals (IRWD), Cytokinetics (CYTK), Mersana Therapeutics (MRSN), Ligand Pharmaceuticals (LGND), Heron Therapeutics (HRTX), Dicerna Pharmaceuticals (DRNA), ZEALAND PHARMA/S (ZEAL), Rocket Pharmaceuticals (RCKT) and Arcus Biosciences (RCUS). View all competitors. What other stocks do shareholders of Beyondspring own? Based on aggregate information from My MarketBeat watchlists, some companies that other Beyondspring investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Enterprise Products Partners (EPD), Fulcrum Therapeutics (FULC), Novavax (NVAX), Sorrento Therapeutics (SRNE), Verizon Communications (VZ) and Bristol-Myers Squibb (BMY). Who are Beyondspring's key executives? Beyondspring's management team includes the following people: Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 48)Mr. Dongheng Liu, Chief Financial Officer (Age 37)Mr. Richard J. Daly M.B.A., Chief Operating Officer (Age 58)Dr. Ramon W. Mohanlal, Exec. VP of R&D and Chief Medical Officer (Age 61)Dr. G. Kenneth Lloyd, Chief Scientific Officer (Age 75) When did Beyondspring IPO? (BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO. What is Beyondspring's stock symbol? Beyondspring trades on the NASDAQ under the ticker symbol "BYSI." Who are Beyondspring's major shareholders? Beyondspring's stock is owned by many different retail and institutional investors. Top institutional shareholders include Jefferies Group LLC (0.51%), Monashee Investment Management LLC (0.33%), Marshall Wace LLP (0.30%), Goldman Sachs Group Inc. (0.27%), Russell Investments Group Ltd. (0.17%) and Marshall Wace North America L.P. (0.14%). Which institutional investors are selling Beyondspring stock? BYSI stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., and UBS Group AG. Which institutional investors are buying Beyondspring stock? BYSI stock was purchased by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Monashee Investment Management LLC, Marshall Wace LLP, Marshall Wace North America L.P., Nuveen Asset Management LLC, California Public Employees Retirement System, Blair William & Co. IL, and Russell Investments Group Ltd.. How do I buy shares of Beyondspring? Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Beyondspring's stock price today? One share of BYSI stock can currently be purchased for approximately $15.23. How big of a company is Beyondspring? Beyondspring has a market capitalization of $458.54 million. The company earns $-38,080,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. What is Beyondspring's official website? The official website for Beyondspring is www.beyondspringpharma.com. How can I contact Beyondspring? Beyondspring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected] This page was last updated on 9/19/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
